Search arXiv⌕ Search
Home/Archive/arXiv

arXiv · 1912.08106

A Two-Step Biopolymer Nucleation Model Shows a Nonequilibrium Critical Point

Alexander I. P. Taylor·Lianne D. Gahan·Rosemary A. Staniforth·Buddhapriya Chakrabarti
View original source ↗Read source document ↗Export metadata ↓

Abstract

Biopolymer self-assembly pathways are central to biological activity, but are complicated by the ability of the monomeric subunits of biopolymers to adopt different conformational states. As a result, biopolymer nucleation often involves a two-step mechanism where the monomers first condense to form a metastable intermediate, and this then converts to a stable polymer by conformational rearrangement of its constituent monomers. While existing mathematical models neglect the dynamics by which intermediates convert to stable polymers, experiments and simulations show that these dynamics frequently occur on comparable timescales to condensation of intermediates and growth of mature polymers, and thus cannot be ignored. Moreover, nucleation intermediates are responsible for cell toxicity in pathologies such as Alzheimer's, Parkinson's, and prion diseases. Due to the relationship between conformation and biological function, the slow conversion dynamics of these species will strongly affect their toxicity. In this study, we present a modified Oosawa model which explicitly accounts for simultaneous assembly and conversion. To describe the conversion dynamics, we propose an experimentally motivated initiation-propagation (IP) mechanism in which the stable phase arises locally within the intermediate, and then spreads through additional conversion events induced by nearest-neighbor interactions, analogous to one-dimensional Glauber dynamics. Our mathematical analysis shows that the competing timescales of assembly and conversion result in a nonequilibrium critical point, separating a regime where intermediates are kinetically unstable from one where conformationally mixed intermediates can accumulate. Our work provides the first general model of two-step biopolymer nucleation, which can be used to quantitatively predict the concentration and composition of biologically crucial intermediates.

Explore related subjects

q-bio.BMcond-mat.softcond-mat.stat-mech

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Alexander I. P. Taylor, Lianne D. Gahan, Rosemary A. Staniforth, Buddhapriya Chakrabarti. 2019-12-17. A Two-Step Biopolymer Nucleation Model Shows a Nonequilibrium Critical Point. https://doi.org/10.1063/5.0009394

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

In Vivo Length Distributions as Mechanistic Fingerprints of Pathological Protein Aggregation

Modern imaging techniques can resolve individual pathological protein aggregates in postmortem human samples, providing detailed measurements of aggregate size distributions that are inaccessible with conventional bulk approaches. These distributions represent mechanistic fingerprints of the microscopic processes that generated the observed pathology, but extracting this mechanistic information requires a quantitative theoretical framework. Here, we develop the mathematical tools needed to interpret aggregate length distributions in living systems, where aggregate growth competes with active removal. We show that, across a class of models, the length distribution of sufficiently large aggregates approaches a geometric decay. Crucially, the decay rate is determined by the balance between aggregate elongation and removal, providing a direct quantitative readout of these competing processes from a single time point measurement. This enables mechanistic comparisons between healthy and diseased human samples without requiring longitudinal measurements of aggregate dynamics. We further analyse how additional aggregation and removal processes modify the observed length distributions. Together, these results establish the mathematical foundations and tools to use aggregate length distributions as an experimentally accessible route for inferring microscopic aggregation dynamics directly from human tissue.

q-bio.BM↗
arXiv2026

Decoding enzyme-substrate interaction topology reveals principles underlying catalytic efficiency and mutational outcomes

The enzyme turnover number (kcat) defines catalytic efficiency and constrains quantitative models of metabolism, yet the molecular determinants governing kcat and its response to mutation remain poorly understood. Measurements are sparse and labor-intensive, and most computational approaches provide numerical predictions without explaining how enzyme-substrate interactions shape catalytic outcomes. A central challenge is therefore to identify the topological principles that determine where mutations act and how their functional outcomes are encoded within the enzyme-substrate interaction network. Here, we show that catalytic efficiency and mutational effects can be interpreted through enzyme-substrate interaction topology. We developed Interkcat, an interpretable bidirectional cross-attention framework that captures reciprocal coordination between protein residues and substrate atoms. Optimized on a unified benchmark, Interkcat achieves state-of-the-art predictive performance (R2 = 0.701). From its learned representations, we derive an Interaction Topology Score (ITS) that identifies sequence regions statistically enriched for mutation-sensitive sites without explicit structural inputs. We further demonstrate that higher-order topological features distinguish opposing mutational outcomes: lethal mutations disrupt coordinated networks, whereas activity-preserving or enhancing mutations retain sparse, globally organized coupling. These findings establish interaction topology as a unifying principle linking enzyme sequence, catalytic efficiency, and evolutionary perturbation.

q-bio.BM↗
arXiv2026

Adapting Boltz-2 with limited experimental activity data improves early enrichment in virtual screening

Virtual screening aims to prioritize active compounds from large chemical libraries within a limited experimental budget. When applying Boltz-2 to virtual screening, a key challenge is how to use limited experimental data from the target assay to improve the prioritization of active compounds. We investigated whether fine-tuning the Boltz-2 affinity heads with a small number of binary activity labels could improve early enrichment of active compounds in hit discovery. We compared fine-tuning with 40-300 labels in a retrospective evaluation on eight MF-PCBA targets. With 300 activity measurements, fine-tuning increased the number of actives in the top 1% by a geometric mean of 1.77-fold across the eight targets and improved average precision (AP) by 2.14-fold relative to the control without fine-tuning. We also investigated whether rescoring a subset of candidates could retain the improvement in hit recovery by reranking only the top-ranked Boltz-2 candidates with the fine-tuned head. Restricting rescoring to approximately 10% of the evaluation set retained hit recovery comparable to full rescoring. These findings show that affinity-head fine-tuning with limited activity labels improves early enrichment with Boltz-2 and that this benefit can be retained when rescoring a restricted set of candidates.

q-bio.BM↗